CVS Health Corporation

CVS Health is a health company. The company's segments are: Pharmacy Services, which provides a range of pharmacy benefit management solutions, including plan design offerings and administration, formulary management, and retail pharmacy network management services; Retail/Long-Term Care (LTC), which sells prescription drugs and general merchandise, including over-the-counter drugs, provides health care services through its MinuteClinic? walk-in medical clinics and conducts LTC pharmacy operations; and Health Care Benefits, which provides a range of voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans.
  • TickerCVS
  • ISINUS1266501006
  • ExchangeNew York Stock Exchange
  • SectorFood & Drug Retailers
  • CountryUnited States

CVS Health Corp: 1 director sold

A director at CVS Health Corp sold 49,211 shares at 74.150USD and the significance rating of the trade was 91/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of boar...

Moody's announces completion of a periodic review of ratings of CVS Health Corporation

Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of CVS Health Corporation. Global Credit Research- 22 Mar 2021. New York, March 22, 2021-- Moody's Investors Service has completed a periodic review of the ratings of CVS Health Corporation and other ratings that are associated with the same analytical unit.

Valens Research

Valens Equity Insights and Inflections - 2021 03 16

INOV has been steadily improving UAFRS-based (Uniform) ROA the past few years before the pandemic, thanks to its conversion from a dataset company to a healthcare insight software platform with significant growth opportunities. And yet the market doesn't recognize how this can continue to mean accelerating returns and growth going forward. While the company has one of the few leading healthcare insight platforms not already captured by a major player like UnitedHealthcare, and currently only has a small share of its potential market of revenue over the coming years, as more players in the ...

Valens Research

CVS - Embedded Expectations Analysis - 2021 03 15

CVS Health Corporation (CVS:USA) currently trades below recent averages relative to UAFRS-based (Uniform) earnings, with a 13.5x Uniform P/E, implying bearish expectations for the firm. However, given management's confidence about achieving 2021 guidance, their digital capabilities, and their oncology business, market expectations are overly bearish and equity upside is likely warranted Specifically, management is confident they can deliver on their 2021 guidance, brand drug inflation will drive Pharmacy Services revenue growth, and that Transform Oncology Care now covers 30% of Aetna's insur...

CVS Health Corporation - December 2020 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Valérie GASTALDY

Short term view - CVS CAREMARK CORP : The trend is bullish.

The trend is bullish. Prices are still making progress but the trend is slowing down. The next resistance is at $75.10. The break of $62.80 would endanger the trend.

Valérie GASTALDY

Analyse court terme - CVS CAREMARK CORP : La tendance est haussière.

La tendance est haussière. Les cours progressent encore, mais la tendance s'affaiblit. La prochaine résistance est à 75,10 $. La rupture de 62,80 $ mettrait la tendance en danger.

Valérie GASTALDY

Analyse court terme - CVS CAREMARK CORP : La tendance est haussière.

La tendance est haussière. La baisse récente gagne en vigueur. Le prochain support est à 67,80 $. La tendance serait remise en cause par la rupture de 62,80 $.

Valérie GASTALDY

Short term view - CVS CAREMARK CORP : The trend is bullish.

The trend is bullish. The recent fall is getting more vigorous. The next support is at $67.80. A break below $62.80 would challenge the trend.

CVS Health Corp: 1 director sold

A director at CVS Health Corp sold 49,211 shares at 74.150USD and the significance rating of the trade was 91/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of boar...

Valens Research

Valens Equity Insights and Inflections - 2021 03 16

INOV has been steadily improving UAFRS-based (Uniform) ROA the past few years before the pandemic, thanks to its conversion from a dataset company to a healthcare insight software platform with significant growth opportunities. And yet the market doesn't recognize how this can continue to mean accelerating returns and growth going forward. While the company has one of the few leading healthcare insight platforms not already captured by a major player like UnitedHealthcare, and currently only has a small share of its potential market of revenue over the coming years, as more players in the ...

Valens Research

CVS - Embedded Expectations Analysis - 2021 03 15

CVS Health Corporation (CVS:USA) currently trades below recent averages relative to UAFRS-based (Uniform) earnings, with a 13.5x Uniform P/E, implying bearish expectations for the firm. However, given management's confidence about achieving 2021 guidance, their digital capabilities, and their oncology business, market expectations are overly bearish and equity upside is likely warranted Specifically, management is confident they can deliver on their 2021 guidance, brand drug inflation will drive Pharmacy Services revenue growth, and that Transform Oncology Care now covers 30% of Aetna's insur...

Valens Research

Valens Credit Weekly Insights - 2021 01 20

Valens Credit Research Team highlighted ideas for BZH, MCK, and MGM. They have also provided recent analyses for CVI and CVS, while RIG topped the quantitative outlier report for the week.

Valens Research

Valens Equity Insights and Inflections - 2020 12 22

CBRL has been steadily improving UAFRS-based (Uniform) ROA the past 10 years, thanks to its strong strategy to optimize its restaurant and store business. While the market is pricing the company for returns post-pandemic to decline to multi-year lows absent 2020,the company's strategy primes them for ROA expansion. The company's resiliency through the pandemic, combined with its ability to accelerate growth with its decision to roll-out alcohol puts it in place to see significant return expansion and growth the market is not recognizing. On top of that, management's compensation aligns them ...

Valens Research

CVS - Embedded Expectations Analysis - 2020 12 17

CVS Health Corporation (CVS:USA) currently trades below corporate averages relative to UAFRS-based (Uniform) earnings, with a 14.0x Uniform P/E, implying bearish expectations for the firm. Although management's concerns about coronavirus, their existing capabilities, and Aetna Connected suggest the potential for near-term headwinds, market expectations are overly bearish, and longer-term equity outperformance is likely warranted Specifically, management may lack confidence in their ability to normalize medical utilization levels, continue converting their HealthHUBs in this environment, and f...

Moody's announces completion of a periodic review of ratings of CVS Health Corporation

Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of CVS Health Corporation. Global Credit Research- 22 Mar 2021. New York, March 22, 2021-- Moody's Investors Service has completed a periodic review of the ratings of CVS Health Corporation and other ratings that are associated with the same analytical unit.

CVS Health Corporation - December 2020 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

CVS Health: Update following change in outlook to stable

Our credit view of CVS Health, reflecting its strong market position and prudent financial strategies constrained by its increasing competition and integration risk of Aetna.

Moody's rates CVS' proposed senior unsecured notes Baa2

Rating Action: Moody's rates CVS' proposed senior unsecured notes Baa2. Global Credit Research- 07 Dec 2020. New York, December 07, 2020-- Moody's Investors Service, today assigned a Baa2 rating to CVS Health's proposed new senior unsecured notes offering.

Moody's changes CVS Health's outlook to stable; affirms Baa2 rating

Rating Action: Moody's changes CVS Health's outlook to stable; affirms Baa2 rating. Global Credit Research- 04 Dec 2020. New York, December 04, 2020-- Moody's Investors Service, today changed the outlook for CVS Health to stable from negative and affirmed the company's senior unsecured rating at Baa2.

With a more favourable environment, CVS HEALTH improves to Slightly Positive

CVS HEALTH (US), a company active in the Drug Retailers industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 4 out of 4 stars, as well as its unchanged, moderately risky market behaviour. The title leverages a more favourable environment and raises its general evaluation to Slightly Positive. As of the analysis date December 8, 2020, the closing price was USD 73.86 and its potential was estimated at USD 77.55.

Ford Equity US Rating and Forecast Report

Ford Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch